Johan Ståhl

Carnegie Investment Bank AB is the broker/delear subsidiary of Carnegie Holding AB in Sweden. Headquartered in Stockholm, the firm was founded in 1803 and offers institutional clients several services within research, equity sales and equity capital market transactions (ECM). The Fixed Income unit offers bond research and sales. Carnegie Investment Bank’s research and equity sales enjoy a global position in Nordic equities.

ABG Sundal Collier AB (ABGSC) is the Swedish securities brokerage subsidiary of ABG Sundal Collier ASA, which is owned by ABG Sundal Collier Holding ASA (FRA: DAB, OSE: ASC) in Norway. Headquartered in Stockholm, ABGSC was founded in 1997 and provides securities execution services to institutional investors.

Svenska Handelsbanken AB (Broker) (Handelsbanken-Broker) is the broker/dealer division of Svenska Handelsbanken AB (STO: SHB-A; OTCMKTS: SVNLY) in Sweden. Headquartered in Stockholm, Handelsbanken-Broker was founded in 1871 and provides trading services to large corporates. The firm trades in equities, money market instruments, currencies, commodities and derivatives.

SEB Investment Management AB (SEB IM) is an investment management firm headquartered in Stockholm, Sweden. The firm was founded in 1978 and is a wholly-owned subsidiary of Skandinaviska Enskilda Banken AB (STO: SEB-A, ADR: SKVKY). SEB-IM offers a broad range of funds and tailored portfolios for institutional investors as well as retail and private banking clients.

Nordea Investment Management AB (NIM) is the Swedish investment management subsidiary of Nordea Asset Management Holding AB, itself a subsidiary of Nordea Bank ABp (HEL: NDA-FI, ADR: NRBAY) in Finland. Founded in 1954 as Merita Nordbanken Investment Management, the firm became Nordea Investment Management AB in 2001 when the Nordea name, an abbreviation of Nordic ideas, replaced Unibank, Nordbanken, Merita and Christiania Bank in a joint renaming operation. Headquartered in Stockholm, NIM manages a range of Swedish funds including pension funds, hedge funds, Luxembourg-domiciled SICAVs and funds registered in other Nordic countries for institutional clients.

Part of Livförsäkringsbolaget Skandia, ömsesidigt, Skandia Fonder AB is a company that provides investment advice. The company is based in Stockholm, Sweden. The Swedish company was founded in 1988. Annelie Enquist has been the CEO of the company since 2012.

E. Öhman J:or Fonder AB (Öhman Fonder) is the wholly-owned fund management subsidiary of E. Öhman J:or Asset Management AB, itself a subsidiary of the Dinkelspeil family's E. Öhman J:or AB in Sweden. Formerly known as SalusAnsvar E Öhman Fonder, the firm was founded in 1947 and became E. Öhman J:or Fonder AB in 2005. Headquartered in Stockholm, Öhman Fonder offers fund management and discretionary portfolio management to institutions, insurance companies and wealthy individuals.

Skandinaviska Enskilda Banken AB (Broker) (SEB-Broker) is the broker/dealer division of Skandinaviska Enskilda Banken AB (STO: SEB-A; OTCMKTS: SVKEF), a financial group headquartered in Stockholm, Sweden. Founded in 1856, SEB-Broker provides trading and executions services to their clients.

AMF Tjänstepension AB (Investment Management) (AMF-IM) is the pension fund management arm of AMF Tjänstepension AB, which is jointly owned by the Swedish Trade Union Confederation (LO) and the Confederation of Swedish Enterprise (SAF), locally known as Svenskt Näringsliv. The firm was founded in 1973 and formerly known as AMF Pensionsförsäkring AB. Headquartered in Stockholm, AMF-IM provides occupational pension schemes to corporate clients and private individuals.

Trill Invest AB is an investment services provider founded in 2020. The private company is based in Stockholm, Sweden. The Swedish company's main focus is on investment services.

Cliens Kapitalförvaltning AB is the asset management subsidiary of Cliens Holding AB in Sweden. Headquartered in Stockholm, the firm was founded in 2008 and provides manage funds with different risk profiles for institutions, entrepreneurs and private individuals. Cliens kapitalförvaltning is the Signatory for UNPRI - The United Nations' (UN) Principles for Responsible Investment.

Healthinvest Partners AB (Healthinvest) is an alternative investment management firm headquartered in Stockholm, Sweden. The firm was founded by Anders Hallberg and Carl Bennet in 2006. They are owned by Atle Investment Management AB, which is a subsidiary of Bure Equity AB (STO: BURE). Healthinvest manages HealthInvest Alpha Fund – which is an actively managed global healthcare fund with a value-based approach, and HealthInvest Sustainable Healthcare – a global healthcare fund where the investment philosophy is characterized by medical progress and innovation with a strong focus on sustainability. In addition, the firm manages the fund Avanza Healthcare on behalf of Avanza.

Fjärde AP-fonden (AP4) is the pension fund management subsidiary of the Government of Sweden. Also known as Fourth AP Fund, the firm was founded in 1974 and is headquartered in Stockholm. AP4 provides pension fund management services for employees of Swedish corporations. The firm manages The Fourth Swedish National Pension Fund, which is a buffer fund for the earnings-related part of the state pension scheme. They are a socially responsible investor and signatory to the UN Principles for Responsible Investment which integrates ESG criteria in their investment processes.

Vasakronan AB operates as a real estate development company. The company owns, develops, and manages commercial properties. Its properties are situated in clusters and offer supplementary services to the tenants. The firm's business activities also include office and retail leasing, and green leases and green offices development. The company was founded in 1955 and is headquartered in Stockholm, Sweden.

Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna.

ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden.

Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden.

Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden.

KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden.

SV Health Managers LLP (SVHM) is the investment management subsidiary of SV Life Sciences Advisers LLP in the UK. Established in 2005, the firm was formerly known as SV Life Sciences Managers LLP and changed their name to SV Health Managers LLP in 2017. Based in London, the firm manages the International Biotechnology Trust plc (LSE: IBT), an investment trust vehicle listed on the London Stock Exchange into which corporate and private investors may invest.